Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749300 | 0.82 | MMP13 (0.48) | GPR119TACR1PDK2CYP11B2BACE1 | |
| SCHEMBL7015009 | 0.79 | PDE4A (0.45) | GPR119JAK2JAK1SYK | |
| SCHEMBL3466911 | 0.78 | ROCK2 (0.44) | GPR119TACR1RORCPDK2 | |
| SCHEMBL12184323 | 0.77 | GPR119 (0.55) | GPR119MAPTSMN1; SMN2 | |
| SCHEMBL3548037 | 0.77 | RORC (0.44) | GPR119TACR1RORCHDAC1HDAC2 | |
| SCHEMBL3766313 | 0.76 | GPR119 (0.48) | GPR119TACR1RORCPDK2USP30 | |
| SCHEMBL1513306 | 0.76 | PDK2 (0.49) | GPR119TACR1RORCPDK2HDAC1 | |
| SCHEMBL5754731 | 0.74 | ALDH1A1 (0.44) | GPR119TACR1RORCPDK2USP30 | |
| SCHEMBL4293214 | 0.74 | OPRM1 (0.49) | GPR119TACR1RORCHDAC1HDAC2 | |
| SCHEMBL2352484 | 0.72 | RORC (0.46) | GPR119TACR1RORCJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2566862-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011140161-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140161-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | GPR119 1/4885TACR1 72/4885RORC 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.